Ann: Half Yearly Report and Accounts, page-3

Some good points, Sillazze – yes, it would seem that trofinetide is being manufactured in Europe.

Neuren has made a €4.15 (AU$6.7m) contractual commitment for trofinetide production and a further AU$800,000 commitment for toxicology studies. In total, that’s AU$7.5 million, payable by Neuren by March 2019. Is that correct?

As you suggest, the large quantity of drug being manufactured and the delay in the Phase 3 Rett trial may signal that trials in both Rett and Fragile X will commence simultaneously next year.

A couple of questions…

You say that Neuren has more has more than doubled production compared to their starting intentions – what were the production starting intentions and when were they announced?

Also you say that the increase in production means “other money coming immediately”. Can you explain your reason for thinking this?

Finally, what is your reason for suggesting that the granting of a PRV voucher is worth more than $400 million?